Precigen Reports Q3 2025 Financial Results; PAPZIMEOS Full FDA Approval in August

PRECIGEN, INC.

2025-Q3 EPS reported -$1.36 vs consensus -$0.10 ▼ miss (-1303.5%)

PAPZIMEOS (zopapogene imadenovec-drba) received full FDA approval in August 2025 for adults with RRP.
Over 100 patients registered in PAPZIMEOS Patient Hub; more than 100 million lives covered by private insurance.
Submitted Marketing Authorization Application to EMA for zopapogene imadenovec in November 2025.
Cash, cash equivalents, and investments totaled $123.6 million as of September 30, 2025.
Entered credit facility providing up to $125 million non-dilutive financing; received first tranche of $100 million.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.